Catalyst Biosciences, Inc. (CBIO)
| Previous Close | 1.1300 |
| Open | 1.1200 |
| Bid | 1.0800 x 2200 |
| Ask | 1.0900 x 2900 |
| Day's Range | 1.0707 - 1.1401 |
| 52 Week Range | 1.0700 - 7.5500 |
| Volume | |
| Avg. Volume | 619,012 |
| Market Cap | 34.171M |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.2980 |
| Earnings Date | Aug. 04, 2021 - Aug. 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Aug. 20, 2015 |
| 1y Target Est | 16.60 |
- GlobeNewswire
Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29-December 2, 2021. The fireside chat will be available on-demand for registered attendees via the Piper Sandler conference site beginning Monday, November 22, 2021 at 10:00 am ET until the end of the conference
- GlobeNewswire
Catalyst Biosciences Announces Change in Corporate Strategy
Reports Third Quarter 2021 Operating & Financial ResultsCompany to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a strategic decision to halt the clinical development of MarzAA, report data to date, and seek a buyer for its hemophilia assets. Catalyst plans to focus its resources on its complement the
